Seer Board Unanimously Rejects $2.35/Share Takeover Bid, Citing Significant Undervaluation
SEER sits 18% above its 52-week low of $1.65.
Summary
Seer's Board of Directors has unanimously rejected the revised unsolicited acquisition proposal from the Radoff-JEC Group, which offered $2.35 per share in cash plus a contingent value right. This decision follows the Radoff-JEC Group's improved offer on April 24, which itself was an increase from their initial $2.25 per share proposal on April 13. The board concluded that the revised proposal significantly undervalues the company, citing its cash position, Proteograph product suite, customer adoption, and intellectual property. This rejection signals the board's firm stance that the company is worth more, creating uncertainty around a potential acquisition and potentially setting the stage for further negotiations or a proxy contest. Investors will now watch for Radoff-JEC Group's next move, including a potential higher bid or a push for board changes, as well as any strategic alternatives Seer's board might explore.
At the time of this announcement, SEER was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $110M. The 52-week trading range was $1.65 to $2.41. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.